Completed PHASE2 NCT00004643

Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus

Sponsor: National Center for Research Resources (NCRR)

Conditions Lupus Erythematosus, Systemic

Interventions cytarabine

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Feb 28, 1995

Listed as NCT00004643, this PHASE2 trial focuses on Lupus Erythematosus, Systemic and remains completed. Sponsored by National Center for Research Resources (NCRR), it has been updated 5 times since 1995, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Center for Research Resources (NCRR)
University of Michigan

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.